OrbiMed’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

OrbiMed’s Portfolio MRNS Stock Details MRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-99,525	Closed	-$1.65M	–	140
2019 Q2	$1.65M	Hold	99,525	–	–	0.03%	124
2019 Q1	$1.66M	Sell	99,525 -25,000	-20%	-$360K	0.03%	117
2018 Q4	$1.43M	Sell	124,525 -17,375	-12%	-$352K	0.03%	118
2018 Q3	$5.68M	Hold	141,900	–	–	0.07%	125
2018 Q2	$4.01M	Hold	141,900	–	–	0.05%	130
2018 Q1	$2.17M	Hold	141,900	–	–	0.03%	131
2017 Q4	$4.63M	Hold	141,900	–	–	0.06%	117
2017 Q3	$3.33M	Hold	141,900	–	–	0.03%	126
2017 Q2	$778K	Hold	141,900	–	–	0.01%	133
2017 Q1	$1M	Hold	141,900	–	–	0.01%	129
2016 Q4	$573K	Hold	141,900	–	–	0.01%	127
2016 Q3	$1.03M	Sell	141,900 -75,000	-35%	-$507K	0.01%	131
2016 Q2	$1.1M	Sell	216,900 -24,350	-10%	-$448K	0.01%	124
2016 Q1	$5.19M	Hold	241,250	–	–	0.05%	115
2015 Q4	$7.37M	Buy	+241,250	New	+$7.08M	0.07%	100

Other funds holding MRNS

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

GPCM

Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

VMI

VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

OrbiMed's MRNS Position: Q3 2019 in Review

OrbiMed sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q3 2019, closing a stake of 99,525 shares — an estimated $1.65M sold.

OrbiMed first reported a position in MRNS in Q4 2015 and held it in 15 quarters. The position peaked at $7.37M in Q4 2015. 64 funds tracked by Wall St. Rank hold MRNS as of Q3 2019.

OrbiMed reported no remaining Marinus Pharmaceuticals, Inc position as of Q3 2019 after selling out during the quarter.
OrbiMed sold 99,525 Marinus Pharmaceuticals, Inc shares in Q3 2019, an estimated $1.65M.
OrbiMed first reported a position in Marinus Pharmaceuticals, Inc in Q4 2015 and held it in 15 quarters.
OrbiMed's Marinus Pharmaceuticals, Inc position peaked at $7.37M in Q4 2015.
64 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q3 2019.

Based on OrbiMed's 13F filing for Q3 2019, filed 14 Nov 2019.